Skip to main content

Table 2 Characteristics of patients with “seronegative” and “seropositive” early arthritis at 3 years (n = 617)

From: Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort

  Seronegative
(n = 242)
Seropositive
(n = 375)
P value*
TJC, mean (SD) 3 (5.3) 2.9 (5.3) 0.900
SJC, mean (SD) 1 (2) 1.5 (2.7) 0.034
ESR, mm/h, mean (SD) 12.4 (10.4) 16.6 (14.7) < 0.001
CRP, mg/L mean (SD) 6 (11) 7.3 (11.6) 0.025
DAS28, mean (SD) 2.8 (1.3) 2.9 (1.4) 0.211
DAS28 < 2.6, n (%) 115 (49.4%) 170 (47.4%) 0.634
HAQ-DI, mean (SD) 0.5 (0.6) 0.5 (0.6) 0.980
mTSS, mean (SD) 10.7 (12.1) 16.3 (15.8) < 0.001
Δ mTSS versus baseline, mean (SD) 5.8 (7.9) 10.4 (11.3) < 0.001
2010 ACR/EULAR criteria (≥ 6/7 points), n (%) 189/233 (81.1%) 369/371 (99.4%) <  0.001
 Based on score ≥ 6 166/229 (72.5%) 366/371 (98.7%) < 0.001
 Typical RA erosion 71/242 (29.3%) 235/375 (62.7%) < 0.001
cs and b DMARDs, n (%) 134 (55.6%) 302 (80.8%) < 0.001
cs DMARDs, n (%) 133 (55.2%) 290 (77.5%) < 0.001
b DMARDs, n (%) 10 (4.2%) 67 (17.9%) < 0.001
Corticosteroids, n (%) 59 (24.5%) 130 (34.8%) 0.007
  1. *Pearson’s chi-square test or Fisher’s exact test for categorical data and Wilcoxon test for continuous variables
  2. TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, HAQ-DI Health Assessment Questionnaire Disability Index, mTSS modified total Sharp score, ACR/EULAR American College of Rheumatology/European League Against Rheumatism, RA rheumatoid arthritis, cs conventional synthetic, b biological, DMARD disease-modifying anti-rheumatic drugs
  3. P values were checkedEntries in italics were significant